Oropharyngeal Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

 Oropharyngeal cancer incidence has recently increased, thereby attracting public attention. Like other malignancies of the upper aerodigestive tract, it has been attributed to the carcinogenic effects of tobacco and alcohol use. However, recent evidence shows that a substantial increase in the disease is attributable to the effects of human papillomavirus (HPV). Early oropharyngeal tumors are often asymptomatic, but advanced tumors produce local pain, earache, cervical lymphadenopathy, trismus, odynophagia, dysphagia, hemorrhage, decreased mobility of the tongue, and fistula formation. Capsular rupture doubles the risk of local and distant relapse and triples the risk of regional recurrence. In addition, the survival rate prognosis deteriorates to 50% compared to positive nodes without capsular rupture.

·       The global burden of oropharyngeal squamous cell carcinoma (OPSCC) is estimated to be approximately 95,000 to 112,000 new patients annually. For the last decades, the incidence of OPSCC has been increasing due to an increase in human papillomavirus-positive (HPV+) OPSCC.

Thelansis’s “Oropharyngeal Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Oropharyngeal Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Oropharyngeal Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Oropharyngeal Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Oropharyngeal Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032